we are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists



122,000

135M



Our authors are among the

TOP 1%





WEB OF SCIENCE

Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us? Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected. For more information visit www.intechopen.com



Proteomic Study of Esophageal Squamous Cell Carcinoma

Yi-Jun Qi¹ and Jen-Fu Chiu² ¹College of Medicine, Henan University ²College of Medicine, Shantou University and University of Hong Kong P.R. China

1. Introduction

Comprehensive profiling of genome and transcriptome has identified myriads of alternations at the level of gene and gene expression, which drive malignant development and progression in context of oncology. As a result, qualitative or quantitative changes of protein expression pattern will inevitably ensue during multi-stage of carcinogenesis. In this sense, the proteome is a functional translation of the genome and is the actual manipulator of cellular behavior. Therefore, proteomic profiling of cellular protein constituents should generate the most relevant marker of the functional state of a cell. On the other hand, lack of correlation between mRNA and protein expression have been documented for a variety of genes. Unlike the genome which is static in certain sense, the proteome of a cell is dynamic and changes over time in terms of protein pattern, protein interactions and modifications triggered by external or internal signals[Kolch et al., 2004; Kolch et al., 2005]. Only dynamic information flow through protein circuitry reflects the course of a disease and allows us to track the pathogenetic mechanisms as well as treatment response[Kolch et al., 2005]. Furthermore, examining DNA sequences and measuring mRNA expression do not specify splicing, post-translational modifications, cleavages, protein subcellular localization and complex formations[Banks et al., 2000; Chambers et al., 2000]. There exists a huge information gulf between RNA transcription and protein expression. Proteome represents a much richer source for the functional description of diseases and the biomarker discovery implicated in cancer. Moreover, most of diagnostic assays currently applied in clinical practice are protein-based immunological methods, which are well adapted to standardization and clinical implementation. Proteomic profiling during disease formation and evolution not only provides an integrated understanding of pathogenesis in context of genome and proteome but also holds greater promise to identify the biomarkers of diagnosis and therapeutic targets for diseases such as cancer.

1.1 Epidemiology and etiology of ESCC

Accounting for more than 400,000 deaths per year, esophageal cancer (EC) ranks as the sixth most common cause of cancer-related mortality worldwide[Parkin et al., 2005]. Moreover, about half of world's EC cases newly diagnosed each year occurred in China[Holmes & Vaughan, 2007]. Histologically, esophageal squamous cell carcinoma (ESCC) and esophageal

adenocarcinoma (EAC) contribute to more than 90% of EC[Daly et al., 2000]. In China, ESCC is the predominant histological subtype and account for nearly 90% of all EC[Li et al., 2011]. In developed countries, in contrast, EAC has been increasingly more frequent over the past two decades and has now surpassed the previously more predominant ESCC[Brown et al., 2008; Trivers et al., 2008]. The incidence of ESCC is characterized by its striking geographical distribution across the world. In the extremely high incidence areas, e.g. northern China, the incidence of EC exceeds 100/100 000/year, while the incidence is less than 5/100 000/year in Europe and the USA[Cheng & Day, 1996]. Heavy smoking and alcohol consumption are associated with increased risk of ESCC in developed countries[Brown et al., 2008; Messmann, 2001; Morita et al., 2010], but not major contributing factors in the pathogenesis of ESCC in China, where major risk factors include nutritional deficiency, consumption of pickled vegetables, dietary contamination with nitrosamine or mycotoxin, and low socioeconomic status[Kamangar et al., 2009; Yang et al., 1984]. In light of the poor nutrition status in Linxian, one of the highest incidence areas for ESCC in the world, two large nutrition intervention studies implemented in the late 1980s reported that the combination of selenium/vitamin E/β carotene significantly reduced total mortality, total cancer mortality and stomach cancer incidence[Blot et al., 1993; Li et al., 1993]. High baseline serum selenium concentrations showed strong protective effects on ESCC and stomach cancer in prospective studies[Mark et al., 2000]. Recently, opposing trends in incidence of EAC and ESCC, i.e. decrease of ESCC incidence and reciprocal increase of EAC incidence has been observed not only worldwide but also in high risk areas in China, pointing to the roles of economic level and lifestyle factors in EC pattern change[Devesa et al., 1998; Fan et al., 2008; Hongo et al., 2009]. In addition, familial aggregation of ESCC has been reported in high-risk areas for ESCC[Chang-Claude et al., 1997]. Taken together, these facts indicate that both genetic susceptibility and environmental risk factors contribute to the etiology of ESCC.

1.2 Current situation of clinical management of ESCC

Early detection of ESCC is formidable and the majority of ESCC patients have advanced metastatic disease at initial diagnosis. Therefore, 40-60% ESCC patients are inappropriate for curative resection, which remains the primary treatment of ESCC as it provides sustained palliation of dysphagia and the best chance of cure[Hagymasi & Tulassay, 2007; Triboulet et al., 2001]. Nonetheless, more than 50% ESCC develop recurrence within 2-3 years after surgery[Dresner & Griffin, 2000; Hulscher et al., 2000; Nakagawa et al., 2004]. Moreover, the overall 5-year survival rate is < 10% despite significant improvements in surgical techniques and adjuvant chemoradiation[Lightdale, 1999]. In contrast, the 5-year survival rate for EC patients at early stages could be as high as 90% [Hu et al., 2001]. Long-term survival correlates with stages of EC, as evidenced by 40-62% of 5-year survival rate for stage I and IIA contrasting with 18-25% for stage IIB and III of EC[Iizuka et al., 1989]. This suggests that the reasons for this disappointingly low survival rate include ineffective screening tools for high-risk population, cancer detection at an advanced stage, high-risk for recurrence, lack of targets for treatment, unreliable noninvasive tools to monitor complete response to chemoradiotherapy and so on. Clearly, identification of effective biomarkers for early detection, monitoring tumor progression and potential therapeutic targets offer the best chances to lower the morbidity and mortality of ESCC.

1.3 Molecular biology studies of ESCC and its contribution to clinical management

Extensive molecular biology studies of ESCC have identified a wealth of dysregulated molecular events involved in esophageal carcinogenesis, which cover a broad range of genes

258

with diverse functions, such as vulnerable genes to chemicals, tumor-related genes, tumor suppressor genes, metastasis genes, apoptosis gene, proliferation genes, etc[Enzinger & Mayer, 2003; Greenawalt et al., 2007; Kwong, 2005; Lin et al., 2009]. Moreover, epigenetic alterations, chromosomal changes and transcriptional changes have also been found to play crucial roles in the pathogenesis of ESCC[Abnet et al., 2010; Greenawalt et al., 2007; Wang et al., 2010]. Although these findings improve our general understanding about the molecular biology of ESCC, the appropriate biomarkers for high-risk population screening, for clinical diagnosis and prognosis, for evaluation of treatment efficiency have not been identified yet. Therefore, it is imperative to search more effective biomarkers for such purposes.

2. ESCC analysis by proteomics

2.1 Advantages of proteomics compared with genomics

The completion of human genome sequence did not ensure panacea solutions to all problems related to biological deregulation. In fact, human proteome is far more complex and dynamic than genome sequence. It is estimated that the human genome contains about 32 000 protein coding genes, which code for 100 000 to 10 million proteins due to alternative RNA splicing, overlapping of transcription units, post-translational processing and modifications[Lander et al., 2001; Venter et al., 2001]. Thus, a big disparity between genome and proteome exists, which indicates that the combinatorial diversification of regulatory networks lead to functional evolution of proteins. Through detecting the functioning units, proteomic studies generate a protein fingerprint, which reflects both the intrinsic genetic programme of the cell and the impact of its immediate environment. Therefore, proteomics is valuable for biomarker discovery since its application provides higher opportunity to identify genuine determinants or causal factors involved in biological functions or the pathogenesis of disease.

2.2 Two-dimensional electrophoresis-based proteomic findings of ESCC

Two-dimensional electrophoresis (2DE) has been used for over 30 years now due to its high resolution for the separation of complex protein mixtures. In combination with mass spectrometry, 2DE has been so far the most commonly used method for analyzing protein expression and identity. Our laboratory used 2DE to profile the proteome from ESCC tumors and matched adjacent non-cancer mucosa, and proteome from immortalized esophageal cell line and cancer cell lines. Comparative analysis and MS for protein identification showed that the over-expressions of four proteins were common in ESCC tissues and cancer cell lines, which include tropomyosin isoform 4 (TPM4), prohibitin, peroxiredoxin (PRX1) and manganese superoxide dismutase (MnSOD); the expressions of another three proteins, i.e. stratifin, prohibitin, squamous cell carcinoma antigen 1 (SCCA1), were correlated inversely with dedifferentiation of ESCC[Qi et al., 2005; Qi et al., 2008]. Immunohistochemistry (IHC) analysis showed that loss of expressions of annexin A2 and stratifin were 45% and 64% in ESCC, respectively[Qi et al., 2007a; Qi et al., 2007b; Ren et al., 2010]. Differential expressions of ten proteins including TPM1, SCCA1, stratifin, peroxiredoxin 2 isoform a, alpha B-crystalline, annexin A2, heterogeneous nuclear ribonucleoprotein L (hnRNP L), triosephosphate isomerase1 (TPI), laminA/C, and cyclophilin A (CypA) can be observed as well. Our findings may suggest that these differential proteins contribute to the multistage process of carcinogenesis, tumor progression, and invasiveness of ESCC. Published in the same issue, Zhou et al found 28

proteins aberrantly expressed in ESCC cancer cells with at least three-fold difference between ESCC and normal epithelial cells[Zhou et al., 2005]. The overlap between these two studies was quite small. Only expression of SCCA1 was commonly down-expressed in ESCC, but transgelin showed increased expression in tumor in our study and decreased expression in Zhou's study. The disparity of proteins identified between these two studies may be due to different sample source, different methods used by these two groups, such as laser capture microdissection vs. bulk tissues, 2D-DIGE vs. silver staining. Later, five groups reported proteomic signatures associated with ESCC using ESCC samples collected from different regions of China, including high risk areas for ESCC such as Linzhou, Xinjiang and low risk areas like Beijing and Guangdong, but only four reports displayed details of identified proteins. Interestingly, more overlap of the identified proteins came from Fu's study and ours, both of which used ESCC samples from Linzhou, one of the highest areas for ESCC adjacent to Taihang Mountain[Fu et al., 2007]. The commonly identified proteins with the same change direction included alpha enolase, TPM, tubulin, prohibitin and PRX2. Although the prevalence of ESCC in Xinjiang is comparable to Linzhou, the protein signatures were unique to sample origin, indicative of more important roles of environmental, ethnic or hereditary factors in the carcinogenesis of ESCC[Liu et al., 2011]. It seems that hsp27 was a general molecular events involved in ESCC since four out of five studies observed down-expression in ESCC except ours. Only one among seven studies performed survival assay after identifying the candidate proteins by ESCC proteomic profiling. Du et al. reported that over-expression of calreticulin and GRP78 could predicate poor prognosis of ESCC[Du et al., 2007]. Although 2DE is indeed a very useful method for biomarker discovery, more examinations of the biological functions and the clinical relevance of biomarker candidates involved in ESCC are necessary to verify its clinical value.

Two reports described the proteomic signatures of ESCC with samples from Japan. Nishimori et al. used the agarose IEF gel in the first dimension, which not only allows for large-scale quantitative comparisons of protein expression but also is able to resolve high molecular mass proteins larger than 150 kDa[Nishimori et al., 2006]. As a result, a different protein pattern was revealed, including a few protein candidates with MW > 70 kDa. Western blot and IHC verified the different expression of a 195 kDa protein, periplakin, between cancer and adjacent non-cancer tissues. Not only was the expression of periplakin significantly down-regulated in ESCC but also translocation of periplakin was observed, which localized at cell-cell boundaries in normal epithelium and dysplastic precursor lesions, and disappeared from cell boundaries and shifted to cell cytoplasm in early cancers. The other research group from Japan used unsupervised classification to analyze the 2D-DIGE protein spots and procured the protein signatures most relevant to clinical parameters with progression of ESCC[Hatakeyama et al., 2006]. The authors developed the largest protein database relevant to ESCC, which identified 240 proteins with expression level associated with carcinogenesis, histological differentiation and the number of lymph node metastases. A significant overlapping was observed between the proteins identified in ESCC with other different types of tumor. In addition, Jazii et al did proteomic profiling using ESCC samples from Iran, another high incidence area for ESCC like northern China, and identified six over-expressed proteins and six under-expressed proteins associated with ESCC[Jazii et al., 2006]. However, the authors only used RT-PCR to verify the loss of β tropomyosin in ESCC. The functions of identified proteins associated with the development and progression of ESCC include cytoskeletal/structural organization, transport, chaperon,

oxioreduction, proliferation, glycolysis, cell motility, transcription, signal transduction, suggesting multiple dysregulated pathways involved in ESCC. For better understanding the pathogenesis of ESCC and development of biomarkers, integrated and comprehensive studies on these protein candidates are needed.

An alternative approach to identify novel tumor biomarkers is the assessment of immune response elicited by tumor antigen since the humoral immune response to cancer in humans has been evidenced by the identification of autoantibodies to a variety of intracellular and surface antigens in cancer patients with different types of tumors[Chen et al., 2007; Disis et al., 1997; Hong et al., 2004; Soussi, 2000]. In ESCC, a number of reports have documented the presence of autoantibodies in serum against various proteins, including p53, cytokeratins, myomegalin, TRIM21, peroxiredoxin VI proteins, Hsp70, and CDC25B[Bergqvist et al., 2001; Fujita et al., 2006; Fujita et al., 2008; Liu et al., 2008; Shimada et al., 2007; Shimada et al., 2005; Veale et al., 1988]. The proteomic-based approach to identify panels of tumor antigens and related autoantibodies was introduced by Brichory et al. in 2001, which identified antiannexin I and II antibodies in sera from patients with lung cancer[Brichory et al., 2001]. There have been four articles published by two research groups, which reported the existence of autoantibodies in sera of ESCC patients. The first report was published by Fujita et al from Japan, who used 2DE to resolve protein extracts from ESCC cell line TE-2 as tumor antigens and then probed the blot with sera of ESCC patients, healthy controls and patients with other cancers[Fujita et al., 2006]. One positive spot was identified as PRX VI by MALDI TOF/TOF MS. The frequency of autoantibody against PRX VI was 50% (15/30) in ESCC, only 6.6% (2/30) in health controls and 3.3% (1/30) in colon cancer. Two years later, the same research group discovered augmented concentration of Hsp70 autoantibody in the serum of ESCC patients, which was significantly higher in ESCC patients than gastric and colon cancer, healthy controls[Fujita et al., 2008]. On the other hand, Liu et al. used ESCC tissue protein extracts and autologous sera to search for autoantibodies in ESCC patients and identified autoantibody CDC25B[Liu et al., 2008]. Furthermore, CDC25B expression was significantly higher in ESCC tissues with positive autoantibody CDC25B and significantly correlated with tumor stage. The sensitivity and specificity of autoantibody CDC25B for ESCC detection was 56.7% and 91%, respectively[Dong et al., 2010]. The autoantibodydriven research is indeed a promising approach for the identification of novel serum biomarkers present in ESCC and for the tumor antigen itself, which may aid the diagnosis of ESCC and development of more effective immunotherapies.

Similar to other cancers, development of multiple drug resistance in ESCC is one of major causes of failure to chemotherapy treatment. Furthermore, recent studies have shown that there exists intrinsic sensitivity and resistance to chemotherapy and/or radiotherapy in malignant cells of ESCC, which may predict clinical outcome of ESCC patients receiving neoadjuvant chemotherapy. Prior stratification of ESCC patients according to reliable biomarkers could not only save patients unnecessary adverse effects of chemotherapeutic agents but also render patients more chance to access to alternative curative treatment options. Therefore, it is imperative to define new diagnostic indicators that can reliably predict response to chemotherapy and radiotherapy in advance. A recent study compared the 2DE gels of parental esophageal cancer cell line EC109 and its resistant sub-cell line EC109/CDDP to determine the different proteins spots and identified 44 proteins with potential contribution to chemotherapy resistance[Wen et al., 2010]. In another study, radioactive 2DE proteomic comparative analysis was performed using protein extracts of biopsies from 34 patients with locally advanced EAC receiving neoadjuvant chemotherapy.

The identified proteins with different expression between responders and non-responders were classified into two major families, cytoskeleton proteins and molecular chaperon proteins. Further validation by IHC and RT-PCR showed that weak expression of HSP27 at protein level and mRNA level were associated with non-response to platin-based chemotherapy[Langer et al., 2008]. As serum represents a rich source for biomarker discovery, proteomic spectra were examined using 27 and 12 serum samples of responders and non-responders, respectively, to preoperative chemoradiotherapy in a training set by surface-enhanced laser desorption and ionization coupled with mass spectrometry analysis. A proteomic classifier comprising four mass peaks, at 7 420, 9 112, 17 123 and 12 867 m/z was identified with 93.3% predicative accuracy in the validation set[Hayashida et al., 2005]. Since chemotherapy resistance is a complex and multi-factorial event, proteomic-based studies enable comprehensive characterization of resistance phenotype of malignant cancers, which may lead to identification of potential distinguishing biomarkers between responders and non-responders and lay foundation for further molecular mechanism studies.

In addition of 2DE gel for proteomic studies, surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) is an alternative proteomic tool to profile the serum or other body fluids and define potential protein pattern with diagnostic potential. By profiling of the serum proteome with SELDI-TOF-MS combined with bioinformatics tools, a number of highly sensitive and specific potential diagnosis markers have been revealed in various types of cancers. Wang et al. used weak cation exchange (WCX2) protein chips and SELDI-TOF-MS to profile 130 symptom-free serum samples collected from high-incidence area of ESCC in northern China, Linzhou, which included 63 subjects with normal esophageal mucosa, 40 subjects with basal cell hyperplasia, 27 subjects with dysplasia and 30 ESCC patients. Biomarker pattern's software identified four protein features at m/z of 9 306.61, 13 765.9, 2 942.15 and 15 953.4, which could distinguish normal esophageal epithelium, basal cell hyperplasia, dysplasia and ESCC with satisfactory diagnostic accuracy[Wang et al., 2006]. Xinjiang is one of the high-incidence areas for ESCC and comprise different ethnic peoples including Han decent. Using CM10 protein chips to capture targets from serum, SELDI-TOF-MS and bioinformatics analysis resulted in identification of six protein peaks (m/z 5667, 5790, 5876, 5979, 6043 and 6102) with diagnostic power with sensitivity and specificity of 91.43% and 88.89%, respectively[Xu et al., 2009]. In the case of ESCC profiled by SELDI-TOF-MS, further purification and identification of discriminatory peaks is necessary for development of simple methods for wider clinical application, and to enhance our understanding of the molecular mechanisms of esophageal carcinogenesis as well.

2.3 SILAC-based proteomic findings of ESCC

Quantitative proteomics is one of the hot research fields in post-genomic era, which has been used extensively in oncology to identify biomarkers with diagnostic and therapeutic potential, thereby avoiding proteins without biological importance. In traditional 2DE, quantitative information of protein spots on 2DE gels is represented by staining intensity. Although 2DE is a versatile tool for visualization of thousands of proteins, detection of posttranslational modified isoforms and targeting of protein expression alternations, it has inherent limitations, such as limited resolution of membrane or extreme pI proteins, low sensitivity and throughput, poor reproducibility, etc., which result in only part of proteome uncovered[Ong & Mann, 2005]. In this context, two classes of MS-based quantitative

262

Proteomic Study of Esophageal Squamous Cell Carcinoma

Protein name	T/N ratio	Functions	References
Annexin A2	↑or ↓		[Du et al., 2007; Liu et al., 2011]
Annexin A8	\downarrow		[Nishimori et al., 2006]
		Coloisen den en dent	[Du et al., 2007; Jazii et al., 2006; Liu
Annexin I	↓or↑	Calcium-dependent	et al., 2011; Nishimori et al., 2006;
		phospholipid binding	Zhou et al., 2005; Zhu et al., 2010]
nnexin V	↑	calcium ion binding	[Du et al., 2007]
Annexin VI	\downarrow		[Nishimori et al., 2006]
leticulocalbin	1		[Zhou et al., 2005]
100 A9	Í		[Zhou et al., 2005]
yntaxin binding protein	(\uparrow)		[Liu et al., 2011]
ranslationally controlled tumor		calcium ion binding	
rotein			[Zhu et al., 2010]
inc finger protein 410	1	Zink/DNA binding	[Du et al., 2007]
Iutuant hemoglobin beta chain		0	[Du et al., 2007]
Iyoglobin	Ť	Heme binding	[Zhu et al., 2010]
PM-4-ALK fusion oncoprotein type 2	↓ ↑	NA	[Du et al., 2007; Jazii et al., 2006]
i w i min usion oncoprotein type 2	I	1 1/ 1	[Fu et al., 2007; Liu et al., 2011;
PM	I		Nishimori et al., 2006; Zhou et al.,
1 171	¥		2005]
			-
TPM2	\downarrow		[Jazii et al., 2006; Nishimori et al., 2006; Zhu et al., 2010]
PM1	I		
	↓ ↑		[Qi et al., 2005]
PM3	↑or↓		[Fu et al., 2007; <i>Zhu et al.</i> , 2010]
PM4	Ť		[Qi et al., 2005]
PM isoform	Î		[Fu et al., 2007; Qi et al., 2005]
'inculin	Ļ		[Nishimori et al., 2006]
Capping protein, gelsolin-like	Ļ	Cytoskeleton constituent	[Fu et al., 2007]
mooth muscle myosin heavy chain 11		-,	[Nishimori et al., 2006]
soform SM1	*		
mooth muscle protein	\downarrow		[Liu et al., 2011]
pha-actinin 4	Î		[Fu et al., 2007]
ubulin alpha-6, ubiquitous	<u>↑</u>		[Fu et al., 2007]
ubulin beta-5 chain	↑		[Fu et al., 2007; Qi et al., 2005]
Gamma-actin	↑		[Qi et al., 2005]
eta-actin	↑		[Fu et al., 2007]
CTB protein	1		[Liu et al., 2011]
rofilin-1	<u>↑</u>		[Zhu et al., 2010]
eriplakin	\downarrow		[Nishimori et al., 2006]
Calreticulin	<u>↑</u>	Stress response and	[Du et al., 2007; Jazii et al., 2006]
alreticulin precursor	<u>↑</u>	immunity	[Nishimori et al., 2006]
Ceratin 6A	$(\uparrow$	Intermediate filament	[Du et al., 2007]
eratin 1	$(\uparrow\uparrow)$		[Jazii et al., 2006; Zhou et al., 2005]
eratin 6			[Nishimori et al., 2006]
eratin 8			[Zhou et al., 2005]
	•	Televis It & Cl.	[Nishimori et al., 2006; Zhou et al.,
eratin 13	\downarrow	Intermediate filament	2005]
			[Nishimori et al., 2006; Zhou et al.,
esmin	\downarrow		2005]
imentin	↑		[Nishimori et al., 2006]
		Superoxide dismutase	
InSOD	ſ	activity	[Du et al., 2007; Qi et al., 2005]
roliferation cell nuclear antigen	*	2	[Dec et al. 2007 7]
PCNA)	↑	DNA polymerase activity	[Du et al., 2007; Zhou et al., 2005]
RO1708	↑		[Du et al., 2007]
Dank-type molecular chaperone	, ,	Stress response and	
ISPAIL	\uparrow or \downarrow	chaperone binding	[Du et al., 2007; Nishimori et al., 2000
DnaJ(Hsp40) homolog	↑	1 0	[Nishimori et al., 2006]
	I		

Proteomics – Human Diseases and Protein Functions

Protein name	T/N ratio	Functions	References				
Heat shock protein 27 kDa	\downarrow or \uparrow		[Du et al., 2007; Fu et al., 2007; <i>Liu et al.</i> , 2011; Zhou et al., 2005]				
Similar to heat shock congnate 71-kDa	↑		[Du et al., 2007]				
protein	I						
Heat shock 70kDa protein 8	\downarrow		[Nishimori et al., 2006]				
Heat shock protein 70 kDa	Ť		[Jazii et al., 2006]				
gp96	Ť		[Zhou et al., 2005]				
GRP78	Ť		[Du et al., 2007]				
Alpha-B-Crystalline	\downarrow		[Qi et al., 2005; Zhu et al., 2010]				
Fibrin beta	(\rightarrow)		[Liu et al., 2011]				
Crystal structure of huma recombinant	$\uparrow \neg$	NA	[Du et al. 2007]				
procathepsin B	(\mathbf{U})		[Du et al., 2007]				
M2-type pyruvate kinase	↑or ↑		[Du et al., 2007; Fu et al., 2007; Liu et al., 2011]				
Mutant beta-actin(Q6F5I1)	Ť		[Du et al., 2007]				
Phosphoglycerate kinase 1	ŕ		[Du et al., 2007; Nishimori et al., 2006]				
			[Du et al., 2007; Fu et al., 2007;				
Alpha enolase	Ť	Energy metabolism	Nishimori et al., 2006; Qi et al., 2005]				
Beat-enolase	Ť	87	[Fu et al., 2007]				
Triosephosphate isomerase	ŕ		[Zhu et al., 2010]				
GAPDH	ŕ		[Qi et al., 2005]				
Aldolase A	i.		[Nishimori et al., 2006]				
Fructose-bisphosphate aldolase A	ľ		[Zhu et al., 2010]				
RNA binding motif protein 8A	∙ ↑	mRNA/nucleotide/protei	[Zhou et al., 2005]				
	*	n binding					
Translation initiation factor Eif-1A	 ★	Translation	[Zhou et al., 2005]				
Transmembrane protein 4	Î		[Zhou et al., 2005]				
Transgelin	↓or ↑	Protein binding	[Liu et al., 2011; Qi et al., 2005; Zhou				
-	*	0	et al., 2005; Zhu et al., 2010]				
COMT protein	Ţ		[Liu et al., 2011]				
Early endosome antigen 1	Ļ	D (1 1 1	[Liu et al., 2011]				
Crystal structure of recombinant human	<u>↑</u>	Protein binding	[Nishimori et al., 2006]				
fibrinogen fragment							
Similar to ubiquitin -conjugating	\downarrow		[Du et al., 2007]				
enzyme E2 variant 1 isoform	^		[Zhow at al. 2005]				
Ubiquitin C-terminal esterase Ubiquinol-cytochrome C reductase	I	Protein degradation	[Zhou et al., 2005]				
complex core protein2	noi-cytochrome C reductase		[Nishimori et al., 2006]				
Proteosome	↑		[Liu et al., 2011]				
Galectin-7	I.	Interaction of cells and	[Zhou et al. 2005; Zhu et al. 2010]				
Galectili-7	Ļ	cell-matrix	[Zhou et al., 2005; Zhu et al., 2010]				
Fatty acid-binding protein	+	Lipid metabolism	[Zhou et al., 2005]				
TGase	\square	Protein modification	[Zhou et al., 2005]				
Fascin		actin cross-lining	[Zhou et al., 2005]				
SCCA1	\downarrow	Cysteine proteinase inhibitor	[Qi et al., 2005; Zhou et al., 2005]				
Proteinase inhibitor, Clade B	I	Neutrophil elastase	[Zhou et al., 2005]				
	*	inhibitor					
Thioredoxin perosidase	, ↑	D 1 1	[Zhou et al., 2005; Zhu et al., 2010]				
Peroxiredoxin 1	↑or ↓	Redox homeostasis	[<i>Fu et al., 2007;</i> Qi et al., 2005]				
Peroxiredoxin 2	Ļ	<u> </u>	[Jazii et al., 2006; Qi et al., 2005]				
ARK family 1	Î	Carcinogen metabolism	[Zhou et al., 2005]				
GST M ₂	↑	glutathione transferase activity	[Zhou et al., 2005]				
Proteasome subunit βtype 4	↑		[Zhou et al., 2005]				
Proteasome subunit βtype 9	j	Protein degradation	[Zhou et al., 2005]				
Prosomal protein p30-33k	↓ ↑		[Zhou et al., 2005]				
Elongation factor Tu	, ↓	Translation	[Qi et al., 2005]				
(NADP) cytoplasmic	, ↓	NAD binding	[Qi et al., 2005]				
(I.	- · · · · · · · · · · · · · · · · · · ·	[x. c. u., _000]				

Proteomic Study of Esophageal Squamous Cell Carcinoma

Protein name	T/N ratio	Functions	References			
Prohibitin	↑or ↓	Transcription regulation	[<i>Fu et al.,</i> 2007; Qi et al., 2005]			
Neuronal protein	↑ == ¥	Neuronal growth	[Qi et al., 2005]			
Nuclear autoantigenic sperm protein	•	Ū.				
isoform 1	Î	Hsp90 protein binding	[Nishimori et al., 2006]			
Myosin heavy chain nonmuscle form A	\downarrow	Actin binding or	[Nishimori et al., 2006]			
Caldesmon 1 isoform 1	\downarrow	calmodulin binding	[Nishimori et al., 2006]			
Myosin regulatory light chain 2	\downarrow	Ventricular/cardiac muscle isoform	[Jazii et al., 2006; Zhu et al., 2010]			
Myosin light chain 2 Myosin light chain 1	+	Regulatory light chain of myosin	[Jazii et al., 2006] [Zhu et al., 2010]			
Heterogeneous nuclear		inyosin				
ribonucleoprotein A2/B1:B1		RNA binding and	[Nishimori et al., 2006]			
Heterogeneous nuclear ribonucleoprotein A2/B1:A2	Ť	processing	[Nishimori et al., 2006]			
Myosin light chain 3	\downarrow	Regulatory light chain	[Zhu et al., 2010]			
Myosin light polypeptide 6	↑		[Jazii et al., 2006]			
Myosin light chain 6B	Ļ	Regulatory light chain	[Zhu et al., 2010]			
Similar to alpha-fetoprotein	Ļ	NA	[Nishimori et al., 2006]			
Trnasferrin	Ļ	ferric iron binding	[Nishimori et al., 2006]			
Alpha-1-antitrypsin precursor	Ļ	Proteinase inhibitor	[Nishimori et al., 2006]			
Alpha-1-antitrypsin	Ť		[Fu et al., 2007]			
Procollagen-proline	\downarrow	Oxidoreductase activity	[Nishimori et al., 2006]			
Calponin 1, basic	\downarrow	actin binding ; calmodulin binding	[Nishimori et al., 2006]			
DNA directed RNA polymerase B (ropB)	↑	Transcription	[Jazii et al., 2006]			
GH16431P	↑	NA	[Jazii et al., 2006]			
OPTN protein	\downarrow	Protein C-terminus binding	[Fu et al., 2007]			
67 kDa laminin receptor	Ť	0	[Fu et al., 2007]			
TNF receptor associated factor 7 Stratifin	↑ ↓	Signal transduction	[Liu et al., 2011] [Du et al., 2007; Qi et al., 2005]			
Cathepsin D	¢ ↑	Aspartyl proteinase activity	[Liu et al., 2011]			
Chromosome1 open reading frame 8	↑	NA	[Liu et al., 2011]			
Cdc42	i ↑	GTPase activator activity	[Liu et al., 2011]			
LLDBP	Ť	NA	[Liu et al., 2011]			
Adenylate kinase 1	Ļ	Adenylate kinase activity				
General transcription factor IIH	Ļ	Transcription	[Liu et al., 2011]			
Serpin B5 precursor	1		[Zhu et al., 2010]			
Serpin B3	1	serine proteinase inhibitor	[Zhu et al., 2010]			
Transthyretin [Precursor]	(\uparrow)	Thyroid hormone-binding protein	[Zhu et al., 2010]			
Apolipoprotein A-I [Precursor]	\frown	lipid metabolism	[Zhu et al., 2010]			
Peptidyl-prolyl cis-trans isomerase A	Ť	Peptidyl-prolyl cis-trans isomerase activity	[Zhu et al., 2010]			
Cystatin-B	Ţ	Cysteine-type endopeptidase inhibitor activity	[Zhu et al., 2010]			
Serum amyloid P-component [Precursor]	\downarrow	Protein binding	[Zhu et al., 2010]			
Phosphatidylethanolamine-binding	Ļ	Serine-type	[Zhu et al., 2010]			
protein1 Carbonia anhudraga 1		endopeptidase inhibitor				
Carbonic anhydrase 1	↓ 1	Carbonate dehydratase	[Zhu et al., 2010]			
Carbonic anhydrase 3 Creatine kinase M-type	↓ I	activity Creatine kinase activity	[Zhu et al., 2010] [Zhu et al., 2010]			
Creatille Killase Wi-type	\downarrow	Creatine Kindse activity	[Zitu et al., 2010]			

Table 1. Reported differential proteins in esophageal cancer tissues

proteomics methods have been developed, which include extracted ion current (XIC)-based label-free quantification and stable isotope labeling quantification. Stable isotope labeling by amino acids in cell culture (SILAC) is an in vivo metabolic labeling method in which stable isotope-labeled amino acids (Heavy vs. Light amino acids) replace the natural amino acids of preexisting proteome[Ong & Mann, 2006]. We used SILAC medium to label immortalized cells (NE3 and NE6) with heavy stable isotope [U-13C6]-H-Lysine and [U-13C6]-H-Arginine and cancer cells (EC1, EC109, EC9706) with light stable isotope [12C6]-L-Lysine and [12C6]-L-Arginine, respectively. After complete labeling of the cellular proteome, equal quantity of proteins from immortalized cells and cancer cells were mixed and then subjected to SDS-PAGE separation, in-gel trypsin digestion and high performance liquid chromatography online with electrospray ionization-MS/MS analysis (HPLC-ESI-MS/MS). Forty-seven candidate proteins with differential expression were identified with our arbitrary criteria, which contains ratio change > 1.5 folds, \geq 2 peptides for quantification and coefficient of variation < 50%. Then, we characterized the cellular protein expression pattern and secretome derived from cisplatin-resistant sub-cell line EC9706 and its parental sensitive cell line EC9706. By SILAC labeling and MS-based quantification, we successfully identified 74 proteins of cellular origin and 57 proteins of secretome with altered expression levels. Similar to our approach, Kashyap et al. used a SILAC-based quantitative proteomic approach to compare the secretome of ESCC cells with that of non-neoplastic esophageal squamous epithelial cells and identified 120 up-regulated proteins with >2-fold difference in the ESCC secretome[Kashyap et al., 2010]. In addition of previously known increased ESCC biomarkers, i.e. matrix metalloproteinase 1, transferrin receptor, and transforming growth factor beta-induced 68 kDa, a number of novel proteins showed distinct expression pattern, among which protein disulfide isomerase family a member 3 (PDIA3), GDP dissociation inhibitor 2 (GDI2), and lectin galactoside binding soluble 3 binding protein (LGALS3BP) were further validated by immunoblot analysis and immunohistochemical labeling using tissue microarrays. These identified proteins participate in multiple biological functions, including molecular chaperones, cytoskeletal proteins, and members of protein inhibitors family, reducing protein, etc., suggesting multiple dysregulated pathways involving in ESCC.

2.4 Clinical relevance of potential protein biomarkers in ESCC

To answer clinical questions, the protein biomarkers identified by proteomic techniques with potential diagnosis and therapeutic targets for ESCC need to be translated into clinical scenario, which is realized by using clinical samples, such as biopsy samples, resected tissue samples, plasma or serum samples, urine samples, saliva samples, etc. The methods used for validation generally comprise Western blot, IHC and ELISA at protein level, and RT-PCR at transcription level. Using 2DE- and SILAC-based quantitative proteomic approaches, we have identified a total of 78 non-redundant proteins with aberrant expression associated with ESCC, suggesting that these proteins may play functional roles in carcinogenesis of ESCC and may have clinical values. Afterwards, Western blot analysis verified the decreased expressions of three proteins, i.e. SCCA1, TPM1 and aB-Cryst in cancer, in accordance with 2DE quantitative results. At transcription level, SCCA1 mRNA was down-regulated in tumor as well. More importantly, the expression of SCCA1 decreased step by step as a function of precancer lesions progression, which suggests that SCCA1 may take part in the multi-stage transformation of ESCC, even in the earliest stages[Qi et al., 2005]. In the 2DE-based comparative proteomic study using immortalized and cancer cell model, we

Proteomic Study of Esophageal Squamous Cell Carcinoma

Accession no.	Protein name	MW/PI	Scores	Ratio (T/N)	Matched peptides	Functions
TPM3 HUMAN	Tropomyosin alpha-3 chain	32.80/4.53	330.06	0.47	2	Actin binding
TPM4 HUMAN	Tropomyosin alpha-4 chain	28.50/4.52		0.37	2	0
K2C8 HUMAN	Keratin, type II cytoskeletal 8	53.67/5.38		0.51	4	
FSCN1 HUMAN	Fascin	54.50/7.02		0.45	2	
LEG1 HUMAN	Galectin-1	14.71/5.18		0.49	3	Signal
CLIC1 HUMAN 1433E HUMAN	Chloride channel ABP 14-3-3 protein epsilon	26.91/4.94 29.16/4.48		0.63 0.66	4 3	transduction
PRDX1 HUMAN	Peroxiredoxin-1	29.16/4.40		0.66	7	
PRDX2 HUMAN	Peroxiredoxin-2	21.88/5.59		0.65		
PRDX4 HUMAN	Peroxiredoxin-4	30.52/5.85		0.03	52	Redox
PRDX5 HUMAN	Peroxiredoxin-5	22.01/9.93		0.60	2	homeostasis
CBR1 HUMAN	Carbonyl reductase [NADPH]1	30.36/9.53		0.59	2	101100000000
KCRB HUMAN	Creatine kinase B-type	42.62/5.25	711 33	1.67	4	
GSTP1 HUMAN	Glutathione S-transferase P	23.34/5.32		0.45	6	
GDIB HUMAN	Rab GDI beat	50.63/6.08		0.47	2	
DHSA HUMAN	Favoprotein subunit complex II	72.65/7.31		0.5	2	Metabolic process
ACBP HUMAN	Acyl-CoA-binding protein	10.04/6.16	135.03	0.64	2	
PHS HUMAN	PHS 2	11.99/6.33	170.64	0.43	3	
RL27A HUMAN	60S ribosomal protein L27a	16.55/11.7 8	233.25	0.59	2	
RSSA HUMAN	40S ribosomal protein SA	32.83/4.64	298.67	0.58	2	Translation
IF4G1_HUMAN	eIF-4-gamma 1	175.4/5.1	650.5	2.15	_ 14	
NPM HUMAN	Nucleophosmin	32.55/4.49		0.52	2	DNA binding
GRP78 HUMAN	GRP78	72.29/4.92	1869.0 9	0.50	14	Chaperone
CH10 HUMAN	Hsp 10	10.92/9.44	219.29	0.40	3	binding
G6PI HUMAN	Glucose-6-phosphate isomerase	63.11/9.10		0.48	5	
UGDH HUMAN	UDP-glucose 6- dehydrogenase	54.99/6.89	604.20	0.53	2	
PPIA HUMAN	Peptidyl-prolyl isomerase A	18.00/9.05	770.25	0.59	9	
ALDOA HUMAN	Fructose-bisphosphate aldolase A	39.40/9.18	386.91	0.59	2	Energy
PGK1 HUMAN	Phosphoglycerate kinase 1	44.59/9.22		0.50	6	metabolism
G3P HUMAN	GAPDH	36.03/9.26		0.52	8	
IPYR HUMAN	Inorganic pyrophosphatase	32.64/5.47		0.45	3	
ENOA HUMAN	Alpha-enolase		1998.1	0.55	15	
CYTB HUMAN	Cystatin-B	11.13/7.85	144.98	0.43	2	
CPSM HUMAN	Carbamoyl-phosphate synthase 1	164.83/6.3 0	3115.1	0.24	6	
PHB2 HUMAN	Prohibitin-2	33.28/10.2 1	546.79	0.47	2	Transcription
CAND1_HUMAN	TBP-interacting protein 120A	136.3/5.4	617.2	1.8	15	regulation
PSME2 HUMAN	Proteasome activator complex subunit2	27.34/5.33	367.19	0.48	2	Coll avala
MCM7_HUMAN	DNA replication licensing factor MCM7	81.3/6.1	510.8	1.97	13	Cell cycle

Accession no.	Protein name	MW/PI	Scores	Ratio (T/N)	Matched peptides	Functions
ACADV HUMAN	VLCAD	70.35/9.63	841.39	0.35	2	Lipid
ATPA HUMAN	ATP5A1	59.71/9.61	963.07	0.47	5	metabolism
THIL HUMAN	Acetoacetyl-CoA thiolase	45.17/9.63	330.39	0.45	2	metabolism
MIF HUMAN	Macrophage migration inhibitory factor	12.47/9.12	267.01	0.61	3	Cytokine activity
ATPB HUMAN	ATPB-3	56.52/5.14	1704.2	0.40	5	Ion transport
VDAC1 HUMAN	VDAC-1	30.75/9.22	548.36	2.32	2	Anion transport
VPS35_HUMAN	hVPS35	91.6/5.2	602.6	1.67	12	Protein transport
HYOU1 HUMAN	Hypoxia up-regulated protein 1	111.27/5.0 2	1206.8	0.56	2	ATP binding
SMD3 HUMAN	Small nuclear ribonucleoprotein 3	13.91/11.0 7	330.93	0.49	2	mRNA processing

Table 2. Differential proteins between immortalized and cancer cell lines derived from ESCC identified by SILAC-based proteomics

selected Annexin A2 for validation by Western blot and IHC. Stepwise decrease in annexin A2 protein expression was observed when epithelial cell was transformed malignantly. In poorly-differentiated squamous carcinoma, 46% (5/11) of cancer tissue sample lost annexin A2 protein and 36% (4/11) expressed at weak intensity [Qi et al., 2007b]. In a separate study, IHC was used to determine 14-3-30 in 60 cases of ESCC, nearby matched normal esophageal epithelium and a variety of ESCC precursor lesions. High level of 14-3-30 expression was found ubiquitously in normal esophageal epithelium with an immuonstaining score of 8.22 in expression. Protein 14-3-30 was down-regulated stepwise during the multi-stage development of ESCC. Sixty-four percent of poorly-differentiated squamous cancer lost 14-3-3σ expression with a score of 0.45[Qi et al., 2007a]. In agreement with our results, Ren et al. documented that the level of 14-3-30 in terms of mRNA and protein was markedly downregulated in ESCC compared with nearby matched non-cancer tissues. Furthermore, decrease of 14-3-30 expression was correlated with tumor infiltration depth, lymph node metastasis, distant metastasis and lymphovascular invasion and shorter 5-year survival rate[Ren et al., 2010]. Among the different proteins identified by SILAC-based quantitative analysis using immortal cell and cancer cell model, the clinical values of MIF in tumorigenesis of ESCC was determined as well. Not only the increased expression of MIF was detected in cellular protein but also in the conditioned medium of esophageal cancer cell lines EC1, EC109 and EC9706 compared with immortal cell lines NE3 and NE6. Low frequency and very weak expression of MIF was detected predominantly in basal cells in normal esophageal epithelium, with an immunostaining score of 1.13. Pronouncedly upregulated expression of MIF occurred in severe dysplasia compared with weak immunostaining in mild and moderate dysplasia. In ESCC, high frequency of intense expression of MIF was observed with a score of 5.46. Furthermore, high expression of MIF was significantly correlated with advanced clinical stages. ELISA tests revealed that there was an increase trend in serum level of MIF in clinically advanced stage IV compared to stage I-III. Functional studies on MIF indicated that MIF knockdown resulted in decrease in proliferation, clonogenicity, non-adherent growth and invasive potential. Our findings indicate that MIF may play crucial roles in malignant transformation of pathogenesis of EC and MIF could become a potential biomarker for high-risk population screening, assessment

of therapeutic efficiency, prognostic evaluation, and molecular targets of developing novel therapeutic regimen as well. In addition of our proteomic results in ESCC, several other reports have looked at the clinical value of potential biomarkers, including cytokeratin 14, Annexin I, SCCA1/2, calgulanulin B and HSP 60, alpha-actinin 4 and 67 kDa laminin receptor, cathepsin D and PKM2, periplakin, calreticulin and GRP78, galectin-7, anti-CD25B antibody[Dong et al., 2010; Du et al., 2007; Fu et al., 2007; Hatakeyama et al., 2006; Liu et al., 2011; Nishimori et al., 2006; Zhu et al., 2010]. Nevertheless, further extensive studies are still necessary to determine the clinical utility of the identified proteins in tumorigenesis and progression of ESCC.

3. Conclusions

Nowadays, the dilemma for cancer control and management is not due to lack of efficient treatment options but diagnosis at late stages. In the case of ESCC in China, five-year survival rate for early stage tumor reaches around 90%[Hu et al., 2001]. Obviously, to detect tumor as early as possible is the key for reducing the mortality and morbidity of ESCC. It is believed that development of ESCC from normal esophageal epithelium takes at least about 10 years, during which diseased epithelium manifests as basal cell hyperproliferation, dysplasia, carcinoma in situ in terms of morphology and finally evolves to malignant neoplasms. As such, carcinogenesis of ESCC is a multi-stage and dynamic process which accumulates ongoing changes at the level of both gene and protein expression.

Proteomic studies from various research groups worldwide have identified distinct dysregulated protein expression pattern associated with ESCC. The discrepancy might reflect the different etiology, different stages of disease and diverse pathways involved, which makes identification of biomarkers for ESCC difficult. In light of a wealth of potential biomarkers associated with ESCC identified so far in the exploratory phase, future large-scale validation studies involving symptom-free patients with precursor lesions in high-incidence area and ESCC patients compared with controls are essential toward clinical application. Therefore, ultimate translation from laboratory into bedside for ESCC biomarkers will require close collaboration and cooperation between researchers and clinicians to look into the clinical utility in diagnosis at early stage, prognosis and monitoring treatment efficiency for ESCC.

4. Acknowledgement

This work was supported in part by National Natural Science Founding of China (No. 30700366 and No. 81072039) and Cancer Research UK (to Yi-Jun Qi).

5. References

- Abnet, C. C., Freedman, N. D., Hu, N., et al. (2010). A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma. *Nat Genet*, Vol.42, No.9, (Sep), pp: 764-767, ISSN 1546-1718
- Banks, R. E., Dunn, M. J., Hochstrasser, D. F., et al. (2000). Proteomics: new perspectives, new biomedical opportunities. *Lancet*, Vol.356, No.9243, (Nov 18), pp: 1749-1756, ISSN 0140-6736

- Bergqvist, A. S., Bergqvist, M., Brattstrom, D., et al. (2001). Serum p53 autoantibodies as prognostic marker in patients with oesophageal carcinoma. *Anticancer Res,* Vol.21, No.6A, (Nov-Dec), pp: 4141-4145, ISSN 0250-7005
- Blot, W. J., Li, J. Y., Taylor, P. R., et al. (1993). Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. *J Natl Cancer Inst*, Vol.85, No.18, (Sep 15), pp: 1483-1492, ISSN 0027-8874
- Brichory, F. M., Misek, D. E., Yim, A. M., et al. (2001). An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. *Proc Natl Acad Sci U S A*, Vol.98, No.17, (Aug 14), pp: 9824-9829, ISSN 0027-8424
- Brown, L. M., Devesa, S. S. & Chow, W. H. (2008). Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. *J Natl Cancer Inst*, Vol.100, No.16, (Aug 20), pp: 1184-1187, ISSN 1460-2105
- Chambers, G., Lawrie, L., Cash, P., et al. (2000). Proteomics: a new approach to the study of disease. *J Pathol*, Vol.192, No.3, (Nov), pp: 280-288, ISSN 0022-3417
- Chang-Claude, J., Becher, H., Blettner, M., et al. (1997). Familial aggregation of oesophageal cancer in a high incidence area in China. *Int J Epidemiol*, Vol.26, No.6, (Dec), pp: 1159-1165, ISSN 0300-5771
- Chen, G., Wang, X., Yu, J., et al. (2007). Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma. *Cancer Res*, Vol.67, No.7, (Apr 1), pp: 3461-3467, ISSN 0008-5472
- Cheng, K. K. & Day, N. E. (1996). Nutrition and esophageal cancer. *Cancer Causes and Control*, Vol.7, No.1, pp: 33-40, 0957-5243
- Daly, J. M., Fry, W. A., Little, A. G., et al. (2000). Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg, Vol.190, No.5, (May), pp: 562-572; discussion 572-563, ISSN 1072-7515
- Devesa, S. S., Blot, W. J. & Fraumeni, J. F., Jr. (1998). Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. *Cancer*, Vol.83, No.10, (Nov 15), pp: 2049-2053, ISSN 0008-543X
- Disis, M. L., Pupa, S. M., Gralow, J. R., et al. (1997). High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. *J Clin Oncol*, Vol.15, No.11, (Nov), pp: 3363-3367, ISSN 0732-183X
- Dong, J., Zeng, B. H., Xu, L. H., et al. (2010). Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma. J Transl Med, Vol.8, (Sep 3), pp: 81, ISSN 1479-5876
- Dresner, S. M. & Griffin, S. M. (2000). Pattern of recurrence following radical oesophagectomy with two-field lymphadenectomy. *Br J Surg*, Vol.87, No.10, (Oct), pp: 1426-1433, ISSN 0007-1323
- Du, X. L., Hu, H., Lin, D. C., et al. (2007). Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma. J Mol Med (Berl), Vol.85, No.8, (Aug), pp: 863-875, ISSN 0946-2716
- Enzinger, P. C. & Mayer, R. J. (2003). Esophageal cancer. *N Engl J Med*, Vol.349, No.23, (Dec 4), pp: 2241-2252, ISSN 1533-4406
- Fan, Y. J., Song, X., Li, J. L., et al. (2008). Esophageal and gastric cardia cancers on 4238 Chinese patients residing in municipal and rural regions: a histopathological

comparison during 24-year period. *World J Surg*, Vol.32, No.9, (Sep), pp: 1980-1988, ISSN 0364-2313

- Fu, L., Qin, Y. R., Xie, D., et al. (2007). Identification of alpha-actinin 4 and 67 kDa laminin receptor as stage-specific markers in esophageal cancer via proteomic approaches. *Cancer*, Vol.110, No.12, (Dec 15), pp: 2672-2681, ISSN 0008-543X
- Fujita, Y., Nakanishi, T., Hiramatsu, M., et al. (2006). Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. *Clin Cancer Res,* Vol.12, No.21, (Nov 1), pp: 6415-6420, ISSN 1078-0432
- Fujita, Y., Nakanishi, T., Miyamoto, Y., et al. (2008). Proteomics-based identification of autoantibody against heat shock protein 70 as a diagnostic marker in esophageal squamous cell carcinoma. *Cancer Lett*, Vol.263, No.2, (May 18), pp: 280-290, ISSN 0304-3835
- Greenawalt, D. M., Duong, C., Smyth, G. K., et al. (2007). Gene expression profiling of esophageal cancer: comparative analysis of Barrett's esophagus, adenocarcinoma, and squamous cell carcinoma. *Int J Cancer*, Vol.120, No.9, (May 1), pp: 1914-1921, ISSN 0020-7136
- Hagymasi, K. & Tulassay, Z. (2007). [Genetic background of esophageal squamous cell carcinoma]. *Orv Hetil*, Vol.148, No.38, (Sep 23), pp: 1795-1800, ISSN 0030-6002
- Hatakeyama, H., Kondo, T., Fujii, K., et al. (2006). Protein clusters associated with carcinogenesis, histological differentiation and nodal metastasis in esophageal cancer. *Proteomics*, Vol.6, No.23, (Dec), pp: 6300-6316, ISSN 1615-9853
- Hayashida, Y., Honda, K., Osaka, Y., et al. (2005). Possible prediction of chemoradiosensitivity of esophageal cancer by serum protein profiling. *Clin Cancer Res*, Vol.11, No.22, (Nov 15), pp: 8042-8047, ISSN 1078-0432
- Holmes, R. S. & Vaughan, T. L. (2007). Epidemiology and pathogenesis of esophageal cancer. *Semin Radiat Oncol*, Vol.17, No.1, (Jan), pp: 2-9, ISSN 1053-4296
- Hong, S. H., Misek, D. E., Wang, H., et al. (2004). An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. *Cancer Res*, Vol.64, No.15, (Aug 1), pp: 5504-5510, ISSN 0008-5472
- Hongo, M., Nagasaki, Y. & Shoji, T. (2009). Epidemiology of esophageal cancer: Orient to Occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol, Vol.24, No.5, (May), pp: 729-735, ISSN 1440-1746
- Hu, Y. C., Lam, K. Y., Law, S., et al. (2001). Identification of differentially expressed genes in esophageal squamous cell carcinoma (ESCC) by cDNA expression array: overexpression of Fra-1, Neogenin, Id-1, and CDC25B genes in ESCC. *Clin Cancer Res*, Vol.7, No.8, (Aug), pp: 2213-2221, ISSN 1078-0432
- Hulscher, J. B., van Sandick, J. W., Tijssen, J. G., et al. (2000). The recurrence pattern of esophageal carcinoma after transhiatal resection. J Am Coll Surg, Vol.191, No.2, (Aug), pp: 143-148, ISSN 1072-7515
- Iizuka, T., Isono, K., Kakegawa, T., et al. (1989). Parameters linked to ten-year survival in Japan of resected esophageal carcinoma. Japanese Committee for Registration of Esophageal Carcinoma Cases. *Chest*, Vol.96, No.5, (Nov), pp: 1005-1011, ISSN 0012-3692
- Jazii, F. R., Najafi, Z., Malekzadeh, R., et al. (2006). Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in


esophageal cancer. World J Gastroenterol, Vol.12, No.44, (Nov 28), pp: 7104-7112, ISSN 1007-9327

- Kamangar, F., Chow, W. H., Abnet, C. C., et al. (2009). Environmental causes of esophageal cancer. *Gastroenterol Clin North Am*, Vol.38, No.1, (Mar), pp: 27-57, vii, ISSN 1558-1942
- Kashyap, M. K., Harsha, H. C., Renuse, S., et al. (2010). SILAC-based quantitative proteomic approach to identify potential biomarkers from the esophageal squamous cell carcinoma secretome. *Cancer Biol Ther*, Vol.10, No.8, (Oct 15), pp: 796-810, ISSN 1555-8576
- Kolch, W., Mischak, H., Chalmers, M. J., et al. (2004). Clinical proteomics: a question of technology. *Rapid Commun Mass Spectrom*, Vol.18, No.19, pp: 2365-2366, ISSN 0951-4198
- Kolch, W., Mischak, H. & Pitt, A. R. (2005). The molecular make-up of a tumour: proteomics in cancer research. *Clin Sci (Lond)*, Vol.108, No.5, (May), pp: 369-383, ISSN 0143-5221
- Kwong, K. F. (2005). Molecular biology of esophageal cancer in the genomics era. *Surg Clin North Am*, Vol.85, No.3, (Jun), pp: 539-553, ISSN 0039-6109
- Lander, E. S., Linton, L. M., Birren, B., et al. (2001). Initial sequencing and analysis of the human genome. *Nature*, Vol.409, No.6822, (Feb 15), pp: 860-921, ISSN 0028-0836
- Langer, R., Ott, K., Specht, K., et al. (2008). Protein expression profiling in esophageal adenocarcinoma patients indicates association of heat-shock protein 27 expression and chemotherapy response. *Clin Cancer Res*, Vol.14, No.24, (Dec 15), pp: 8279-8287, ISSN 1078-0432
- Li, B., Taylor, P. R., Li, J. Y., et al. (1993). Linxian nutrition intervention trials. Design, methods, participant characteristics, and compliance. *Ann Epidemiol*, Vol.3, No.6, (Nov), pp: 577-585, ISSN 1047-2797
- Li, L. W., Li, Y. Y., Li, X. Y., et al. (2011). A novel tumor suppressor gene ECRG4 interacts directly with TMPRSS11A (ECRG1) to inhibit cancer cell growth in esophageal carcinoma. *BMC Cancer*, Vol.11, (Feb 3), pp: 52, ISSN 1471-2407
- Lightdale, C. J. (1999). Esophageal cancer. American College of Gastroenterology. *Am J Gastroenterol*, Vol.94, No.1, (Jan), pp: 20-29, ISSN 0002-9270
- Lin, D. C., Du, X. L. & Wang, M. R. (2009). Protein alterations in ESCC and clinical implications: a review. *Dis Esophagus*, Vol.22, No.1, pp: 9-20, ISSN 1442-2050
- Liu, W. L., Zhang, G., Wang, J. Y., et al. (2008). Proteomics-based identification of autoantibody against CDC25B as a novel serum marker in esophageal squamous cell carcinoma. *Biochem Biophys Res Commun*, Vol.375, No.3, (Oct 24), pp: 440-445, ISSN 1090-2104
- Liu, Z., Feng, J. G., Tuersun, A., et al. (2011). Proteomic identification of differentiallyexpressed proteins in esophageal cancer in three ethnic groups in Xinjiang. *Mol Biol Rep*, Vol.38, No.5, (Jun), pp: 3261-3269, ISSN 1573-4978
- Mark, S. D., Qiao, Y. L., Dawsey, S. M., et al. (2000). Prospective study of serum selenium levels and incident esophageal and gastric cancers. *J Natl Cancer Inst*, Vol.92, No.21, (Nov 1), pp: 1753-1763, ISSN 0027-8874
- Messmann, H. (2001). Squamous cell cancer of the oesophagus. Best Pract Res Clin Gastroenterol, Vol.15, No.2, (Apr), pp: 249-265, ISSN 1521-6918

- Morita, M., Kumashiro, R., Kubo, N., et al. (2010). Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: epidemiology, clinical findings, and prevention. *Int J Clin Oncol*, Vol.15, No.2, (Apr), pp: 126-134, ISSN 2547-7772
- Nakagawa, S., Kanda, T., Kosugi, S., et al. (2004). Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. *J Am Coll Surg*, Vol.198, No.2, (Feb), pp: 205-211, ISSN 1072-7515
- Nishimori, T., Tomonaga, T., Matsushita, K., et al. (2006). Proteomic analysis of primary esophageal squamous cell carcinoma reveals downregulation of a cell adhesion protein, periplakin. *Proteomics*, Vol.6, No.3, (Feb), pp: 1011-1018, ISSN 1615-9853
- Ong, S. E. & Mann, M. (2005). Mass spectrometry-based proteomics turns quantitative. *Nat Chem Biol*, Vol.1, No.5, (Oct), pp: 252-262, ISSN 1552-4450
- (2006). A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC). *Nat Protoc,* Vol.1, No.6, pp: 2650-2660, ISSN 1750-2799
- Parkin, D. M., Bray, F., Ferlay, J., et al. (2005). Global cancer statistics, 2002. *CA Cancer J Clin*, Vol.55, No.2, (Mar-Apr), pp: 74-108, ISSN 0007-9235
- Qi, Y., Chiu, J. F., Wang, L., et al. (2005). Comparative proteomic analysis of esophageal squamous cell carcinoma. *Proteomics*, Vol.5, No.11, (Jul), pp: 2960-2971, ISSN 1615-9853
- Qi, Y. J., He, Q. Y., Ma, Y. F., et al. (2008). Proteomic identification of malignant transformation-related proteins in esophageal squamous cell carcinoma. *J Cell Biochem*, Vol.104, No.5, (Aug 1), pp: 1625-1635, ISSN 1097-4644
- Qi, Y. J., Ma, Y. F., Du, Y. W., et al. (2007a). Character ization and correlation of 14-3-30 and P53 protein expressions in multi-stage carcinogenesis of esophageal squamous cell carcinoma. *J Fourth Mil Med Univ*, Vol.28, No.20, (June 15), pp: 1834-1837, ISSN 1000-5404
- Qi, Y. J., Wang, L. D., Jiao, X. Y., et al. (2007b). [Dysregulation of Annexin II expression in esophageal squamous cell cancer and adjacent tissues from a high-incidence area for esophageal cancer in Henan province]. *Ai Zheng*, Vol.26, No.7, (Jul), pp: 730-736, ISSN 1000-467X
- Ren, H. Z., Pan, G. Q., Wang, J. S., et al. (2010). Reduced stratifin expression can serve as an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma. *Dig Dis Sci*, Vol.55, No.9, (Sep), pp: 2552-2560, ISSN 1573-2568
- Shimada, H., Kuboshima, M., Shiratori, T., et al. (2007). Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma. *Int J Oncol*, Vol.30, No.1, (Jan), pp: 97-103, ISSN 1019-6439
- Shimada, H., Nakashima, K., Ochiai, T., et al. (2005). Serological identification of tumor antigens of esophageal squamous cell carcinoma. *Int J Oncol*, Vol.26, No.1, (Jan), pp: 77-86, ISSN 1019-6439
- Soussi, T. (2000). p53 Antibodies in the sera of patients with various types of cancer: a review. *Cancer Res,* Vol.60, No.7, (Apr 1), pp: 1777-1788, ISSN 0008-5472
- Triboulet, J. P., Mariette, C., Chevalier, D., et al. (2001). Surgical management of carcinoma of the hypopharynx and cervical esophagus: analysis of 209 cases. *Arch Surg*, Vol.136, No.10, (Oct), pp: 1164-1170, ISSN 0004-0010

- Trivers, K. F., Sabatino, S. A. & Stewart, S. L. (2008). Trends in esophageal cancer incidence by histology, United States, 1998-2003. Int J Cancer, Vol.123, No.6, (Sep 15), pp: 1422-1428, ISSN 1097-0215
- Veale, R. B., Thornley, A. L., Scott, E., et al. (1988). Quantitation of autoantibodies to cytokeratins in sera from patients with squamous cell carcinoma of the oesophagus. *Br J Cancer*, Vol.58, No.6, (Dec), pp: 767-772, ISSN 0007-0920
- Venter, J. C., Adams, M. D., Myers, E. W., et al. (2001). The sequence of the human genome. *Science*, Vol.291, No.5507, (Feb 16), pp: 1304-1351, ISSN 0036-8075
- Wang, L. D., Wang, D. C., Zheng, S., et al. (2006). [Serum proteomic profiles of the subjects with esophageal precancerous and cancerous lesions from Linzhou, an area with high incidence of esophageal cancer in Henan Province, Northern China]. *Ai Zheng*, Vol.25, No.5, (May), pp: 549-554, ISSN 1000-467X
- Wang, L. D., Zhou, F. Y., Li, X. M., et al. (2010). Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54. *Nat Genet*, Vol.42, No.9, (Sep), pp: 759-763, ISSN1546-1718
- Wen, J., Zheng, B., Hu, Y., et al. (2010). Comparative proteomic analysis of the esophageal squamous carcinoma cell line EC109 and its multi-drug resistant subline EC109/CDDP. Int J Oncol, Vol.36, No.1, (Jan), pp: 265-274, ISSN 1791-2423
- Xu, S. Y., Liu, Z., Ma, W. J., et al. (2009). New potential biomarkers in the diagnosis of esophageal squamous cell carcinoma. *Biomarkers*, Vol.14, No.5, (Aug), pp: 340-346, ISSN 1366-5804
- Yang, C. S., Sun, Y., Yang, Q. U., et al. (1984). Vitamin A and other deficiencies in Linxian, a high esophageal cancer incidence area in northern China. J Natl Cancer Inst, Vol.73, No.6, (Dec), pp: 1449-1453, ISSN 0027-8874
- Zhou, G., Li, H., Gong, Y., et al. (2005). Proteomic analysis of global alteration of protein expression in squamous cell carcinoma of the esophagus. *Proteomics*, Vol.5, No.14, (Sep), pp: 3814-3821, ISSN 1615-9853
- Zhu, X., Ding, M., Yu, M. L., et al. (2010). Identification of galectin-7 as a potential biomarker for esophageal squamous cell carcinoma by proteomic analysis. *BMC Cancer*, Vol.10, (Jun 15), pp: 290, ISSN 1471-2407





Proteomics - Human Diseases and Protein Functions Edited by Prof. Tsz Kwong Man

ISBN 978-953-307-832-8 Hard cover, 438 pages Publisher InTech Published online 10, February, 2012 Published in print edition February, 2012

Biomedical research has entered a new era of characterizing a disease or a protein on a global scale. In the post-genomic era, Proteomics now plays an increasingly important role in dissecting molecular functions of proteins and discovering biomarkers in human diseases. Mass spectrometry, two-dimensional gel electrophoresis, and high-density antibody and protein arrays are some of the most commonly used methods in the Proteomics field. This book covers four important and diverse areas of current proteomic research: Proteomic Discovery of Disease Biomarkers, Proteomic Analysis of Protein Functions, Proteomic Approaches to Dissecting Disease Processes, and Organelles and Secretome Proteomics. We believe that clinicians, students and laboratory researchers who are interested in Proteomics and its applications in the biomedical field will find this book useful and enlightening. The use of proteomic methods in studying proteins in various human diseases has become an essential part of biomedical research.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Yi-Jun Qi and Jen-Fu Chiu (2012). Proteomic Study of Esophageal Squamous Cell Carcinoma, Proteomics -Human Diseases and Protein Functions, Prof. Tsz Kwong Man (Ed.), ISBN: 978-953-307-832-8, InTech, Available from: http://www.intechopen.com/books/proteomics-human-diseases-and-proteinfunctions/proteomic-study-of-esophageal-squamous-cell-carcinoma



InTech Europe

University Campus STeP Ri Slavka Krautzeka 83/A 51000 Rijeka, Croatia Phone: +385 (51) 770 447 Fax: +385 (51) 686 166 www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai No.65, Yan An Road (West), Shanghai, 200040, China 中国上海市延安西路65号上海国际贵都大饭店办公楼405单元 Phone: +86-21-62489820 Fax: +86-21-62489821 © 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the <u>Creative Commons Attribution 3.0</u> <u>License</u>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

IntechOpen

IntechOpen